Adaptive Trial Design for Faster Development
Biotechs can accelerate progression from Phase I to Phase II through early patient inclusion, integrated regulatory planning, and seamless CRO partnerships.
Ben Edwards, COO of Avance Clinical, discussed challenges in biotech, emphasizing the importance of addressing preclinical package gaps and obtaining patient data early.
Creating a sound scientific argument for new drugs requires CROs with deep scientific capabilities.
Edwards noted the shift towards adaptive trial designs and the benefits of staying with the same CRO for continuity, requiring integrated teams and data visualization.
Author's summary: Adaptive trial design accelerates biotech development.
- Early patient inclusion
- Integrated regulatory planning
- Seamless CRO partnerships